GlassScriptPhysician profile
Alieta R Eck
NPI 1720093107
$2,430.83
in general payments reported to CMS, 2019-2025
31 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.38 · 2020: $273 · 2021: $405 · 2022: $346 · 2023: $720 · 2024: $235 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060 · Education: $306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.82 |
| Education | $305.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $659.67 | 2021-2025 | Ubrelvy, Qulipta |
| Astellas Pharma US INC | $397.01 | 2023-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $235.46 | 2020-2025 | |
| Abbott Laboratories | $175.02 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $72.09 | 2020-2021 | |
| Lilly USA, LLC | $71.06 | 2020-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.33 | 2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $65.99 | 2022-2023 | Seglentis |
| Novo Nordisk INC | $65.54 | 2020-2025 | Wegovy |
| Pfizer INC. | $55.80 | 2020-2021 | |
| Madrigal Pharmaceuticals | $54.88 | 2025 | Rezdiffra |
| Dexcom, INC. | $47.52 | 2021-2023 | Dexcom G6 Transmitter |
| Bausch Health US, LLC | $38.92 | 2020 | |
| Ibsa Pharma INC. | $37.13 | 2020 | |
| Exact Sciences Corporation | $36.76 | 2023-2024 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $36.64 | 2024 | Crysvita |
| Bayer Healthcare Pharmaceuticals INC. | $32.88 | 2025 | |
| Mannkind Corporation | $32.03 | 2020-2024 | |
| Xeris Pharmaceuticals, INC. | $31.50 | 2023 | Gvoke Hypopen |
| Allergan, INC. | $27.42 | 2019-2020 | |
| Corcept Therapeutics | $26.48 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $23.21 | 2022 | |
| Insulet Corporation | $20.99 | 2025 | Omnipod |
| Medtronic, INC. | $17.77 | 2025 | Minimed 780g |
| Takeda Pharmaceuticals U.S.A., INC. | $15.14 | 2020 | |
| Protega Pharmaceutials INC | $15.00 | 2023 | Roxybond |
| Esperion Therapeutics, INC. | $14.93 | 2021 | |
| Cequr Corporation | $14.53 | 2024 | Cequr Simplicity |
| Collegium Pharmaceutical, INC. | $14.02 | 2021 | |
| Sanofi Pasteur INC. | $13.46 | 2020 | |
| Merck Sharp & Dohme LLC | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alieta Eck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.